MA5-15895

antibody from Invitrogen Antibodies

Targeting: MCM2 BM28, CCNL1, cdc19, CDCL1, D3S3194, DFNA70, KIAA0030

Provider product page for MA5-15895

Western blot

ELISA

Immunohistochemistry

Flow cytometry

Other assay

Antibody data

Antibody Data
Antigen structure
References [3]
Comments [0]
Validations
Flow cytometry [1]
Other assay [3]

Submit

Product number: MA5-15895 - Provider product page
Provider: Invitrogen Antibodies
Product name: MCM2 Monoclonal Antibody (2B3)
Antibody type: Monoclonal
Antigen: Purifed from natural sources
Description: MA5-15895 targets MCM2 in indirect ELISA, FACS, IHC, and WB applications and shows reactivity with Human, mouse, Non-human primate, and Rat samples. The MA5-15895 immunogen is purified recombinant fragment of human MCM2 expressed in E. Coli. . MA5-15895 detects MCM2 which has a predicted molecular weight of approximately 125kDa.
Reactivity: Human, Mouse, Rat
Host: Mouse
Isotype: IgG
Antibody clone number: 2B3
Vial size: 100 µL
Concentration: Conc. Not Determined
Storage: Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

MCM2 protein structure - MA5-15895 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 4 HTR2B receptor agonist treatment increases beta-cell proliferation in vitamin B6-deficient dams and normalizes glucose tolerance at GD 16.5. Shown in ( A ) is representative x20 immunofluorescent images of GD 12.5 pancreases from PBS and HTR2B agonist injected control and vitamin B6-deficient (VB6D) mice. Proliferating beta-cells are identified using MCM-2 and Insulin antibodies and calculated as percentage of total beta-cells ( B ). Glucose AUC for PBS and HTR2B agonist-treated control and VB6D dams at GD 16.5 is shown in ( C ). Data for panels A and B are based on 40-50 islets per mouse ( N = 3 mice), while panel C represents 5-7 mice. Two-way ANOVA tests performed in panels B and C revealed a diet x treatment interaction effect and post hoc Tukey''s multiple comparison tests were subsequently performed. * p

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 PHA-767491 inhibits the function of canonical targets Cdc7 and Cdk9. PHA-767491 inhibits the phosphorylation of both RNAPII (S2) and MCM2 (S40) in (A) Jurkat cells and (B) OT-I CTL. The cells were incubated with the respective inhibitors for the indicated duration. Raw values for the band intensities are shown below the respective bands. Representative blots of three independent experiments are shown. The averaged values of the ratio of the band intensities for both RNAPII and MCM2, normalized to their respective 0 h samples, are shown in bar charts to the right. Bar charts are represented as mean +- SEM. Statistical significance was determined by unpaired two-sided Student's t -test (n.s, non-significant; * p < 0.05; ** p < 0.01; *** p < 0.001).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 7 PHA-767491 modulates TCR signaling. (A) PHA-767491 treatment suppresses Erk phosphorylation. Immunoblots of OT-I CTL that were not-treated (-) or were treated (+) with PHA-767491 were stimulated with K b -OVA tetramers for the indicated times. Normalized values of individual bands are indicated below the respective bands. Representative blots of at least three independent experiments are shown. (B) The ratio of the band intensities of the phosphorylated proteins to the respective total proteins from (A) are shown in the bar charts, depicted as mean +- SEM. Values represent fold change, normalized to the DMSO-treated sample values for the respective time points. (C) PHA-767491 does not impair Ca 2+ flux. Peripheral lymphocytes were either pre-treated with PHA-767491 or not and were incubated with biotinylated anti-CD3 antibodies. Lymphocytes were first cross-linked using streptavidin, followed by an exogenous addition of CaCl 2 solution, and finally treated with ionomycin. (D) PHA-767491 affects TCR recycling in stimulation assays. Peripheral lymphocytes and thymocytes were stimulated with plate-bound anti-CD3 antibody or anti-CD3/CD28 beads, respectively, for 3 or 17 h. Values indicated in the histograms represent the MFI. (E) Cdc7 association with Dbf4 and MCM2 is reduced in TCR stimulated T cells treated with PHA-767491. Serum-starved Jurkat cells that were not-treated (-) or treated (+) with PHA-767491 were seeded into wells coated with plate-bound a